Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKelvin ZhengJCJessica Caro

Discussion

Loading...

Member takes

Overview

Real-world analysis shows infections in multiple myeloma patients treated with teclistamab are common, highlighting the need for better management strategies.

Key Points

  • Infections in teclistamab-treated multiple myeloma patients were common and often severe, resulting in hospitalizations.
  • Median time to first infection was 37 days, with notable association of IVIG with infection rates and overall survival.
  • Retrospective cohort analysis utilized electronic medical records to assess infection types and risk factors.
  • Findings indicate a need for routine immunoglobulin monitoring and consideration of prophylaxis to improve patient outcomes.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1cehttps://doi.org/10.1182/blood-2025-7511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  2. 2Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma2025
  3. 3Real-world outcomes of teclistamab in triple-exposed relapsed/refractory multiple myeloma: Brazilian single-center experience2025
  4. 4Low-dose teclistamab in newly diagnosed multiple myeloma patients2025 · 1 citations
  5. 5Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea2025 · 3 citations